Holen Sie sich die Stockscreener-App
2.56
3.76%
-0.10
Handel nachbörslich:
2.53
-0.03
-1.17%
Schlusskurs vom Vortag:
$2.66
Offen:
$2.64
24-Stunden-Volumen:
1.70M
Relative Volume:
0.48
Marktkapitalisierung:
$143.13M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
256.00
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
+20.19%
1M Leistung:
+319.67%
6M Leistung:
+120.69%
1J Leistung:
+76.55%
1-Tages-Spanne:
$2.52
$2.685
1-Wochen-Bereich:
$2.35
$2.95
52-Wochen-Spanne:
$0.5052
$2.95
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.56 | 119.09M | 76.19M | -1.61M | 28.98M | 0.01 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey
Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN
Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN
Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter
Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail
GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com
Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN
Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
GSK, Spero stop UTI drug trial after early success - Reuters
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India
Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com Nigeria
Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia
Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance
Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times
Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune
Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz
New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus
Spero Therapeutics appoints new CEO and board nominee - Investing.com
Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire
Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan
Spero Therapeutics appoints new CEO and board nominee By Investing.com - Investing.com Canada
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):